206 related articles for article (PubMed ID: 34367728)
21. Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.
Cuapio A; Post M; Cerny-Reiterer S; Gleixner KV; Stefanzl G; Basilio J; Herndlhofer S; Sperr WR; Brons NH; Casanova E; Zimmer J; Valent P; Hofer E
Oncotarget; 2016 Jul; 7(29):46466-46481. PubMed ID: 27341131
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.
Estrov Z; Kurzrock R; Estey E; Wetzler M; Ferrajoli A; Harris D; Blake M; Gutterman JU; Talpaz M
Blood; 1992 Apr; 79(8):1938-45. PubMed ID: 1373331
[TBL] [Abstract][Full Text] [Related]
23. Cytokines can reduce clonal, CD34-positive cells in acute myeloid leukemia in vitro.
Braun S; Gerhartz HH; Schmetzer HM
Ann Hematol; 2000 Jul; 79(7):363-73. PubMed ID: 10965784
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia.
Buyse M; Squifflet P; Lucchesi KJ; Brune ML; Castaigne S; Rowe JM
Trials; 2011 Mar; 12():86. PubMed ID: 21429214
[TBL] [Abstract][Full Text] [Related]
25. Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis.
Berry SM; Broglio KR; Berry DA
Cancer Invest; 2011 May; 29(4):293-9. PubMed ID: 21469978
[TBL] [Abstract][Full Text] [Related]
26. In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia.
Tao M; Li B; Nayini J; Sivaraman S; Song S; Larson A; Toofanfard M; Chen H; Venugopal P; Preisler HD
Leuk Lymphoma; 2001 Mar; 41(1-2):161-8. PubMed ID: 11342369
[TBL] [Abstract][Full Text] [Related]
27. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia.
Bernstein SH; Fay J; Frankel S; Christiansen N; Baer MR; Jacobs C; Blosch C; Hanna R; Herzig G
Cancer Chemother Pharmacol; 1999; 43(2):141-4. PubMed ID: 9923819
[TBL] [Abstract][Full Text] [Related]
29. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
Estrov Z; Manna SK; Harris D; Van Q; Estey EH; Kantarjian HM; Talpaz M; Aggarwal BB
Blood; 1999 Oct; 94(8):2844-53. PubMed ID: 10515888
[TBL] [Abstract][Full Text] [Related]
30. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Br J Haematol; 2020 Feb; 188(4):e49-e53. PubMed ID: 31853942
[No Abstract] [Full Text] [Related]
31. Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.
Aurelius J; Möllgård L; Kiffin R; Ewald Sander F; Nilsson S; Thorén FB; Hellstrand K; Martner A
Leuk Lymphoma; 2019 Nov; 60(11):2771-2778. PubMed ID: 30991860
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.
Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA
Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668
[TBL] [Abstract][Full Text] [Related]
33. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM
Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500
[TBL] [Abstract][Full Text] [Related]
34. Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation.
Villatoro A; Cuminetti V; Bernal A; Torroja C; Cossío I; Benguría A; Ferré M; Konieczny J; Vázquez E; Rubio A; Utnes P; Tello A; You X; Fenton CG; Paulssen RH; Zhang J; Sánchez-Cabo F; Dopazo A; Vik A; Anderssen E; Hidalgo A; Arranz L
Nat Commun; 2023 Jan; 14(1):12. PubMed ID: 36596811
[TBL] [Abstract][Full Text] [Related]
35. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro.
Braun S; Gerhartz HH; Schmetzer HM
Haematologia (Budap); 2000; 30(4):271-88. PubMed ID: 11204027
[TBL] [Abstract][Full Text] [Related]
36. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse.
Maraninchi D; Blaise D; Viens P; Brandely M; Olive D; Lopez M; Sainty D; Marit G; Stoppa AM; Reiffers J
Blood; 1991 Nov; 78(9):2182-7. PubMed ID: 1932739
[TBL] [Abstract][Full Text] [Related]
37. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-1β inhibits normal hematopoietic expansion and promotes acute myeloid leukemia progression via the bone marrow niche.
Wang Y; Sun X; Yuan S; Hou S; Guo T; Chu Y; Pang T; Luo HR; Yuan W; Wang X
Cytotherapy; 2020 Mar; 22(3):127-134. PubMed ID: 32024607
[TBL] [Abstract][Full Text] [Related]
39. The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators.
Binder S; Luciano M; Horejs-Hoeck J
Cytokine Growth Factor Rev; 2018 Oct; 43():8-15. PubMed ID: 30181021
[TBL] [Abstract][Full Text] [Related]
40. Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra).
Stosić-Grujicić S; Basara N; Milenković P; Dinarello CA
J Chemother; 1995 Feb; 7(1):67-70. PubMed ID: 7629564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
